Anti-inflammatory/anti-amyloidogenic effects of plasmalogens in lipopolysaccharide-induced neuroinflammation in adult mice

• Published in: Journal of neuroinflammation 2012-08, Vol.9 (1), p.197-197, Article 197
• Main Authors: Ifuku, Masataka, Katafuchi, Toshihiko, Mawatari, Shiro, Noda, Mami, Miake, Kiyotaka, Sugiyama, Masaaki, Fujino, Takehiko
• Format: Article
• Language: English
• Subjects: Advertising executives; Alzheimer's disease; Amyloid beta-Peptides - antagonists & inhibitors; Animals; Anti-Inflammatory Agents - pharmacology; Anti-Inflammatory Agents - therapeutic use; Behavior; Brain Edema - drug therapy; Care and treatment; Chickens; Cognition & reasoning; Fatty acids; Glycerophospholipids - therapeutic use; Health aspects; Immunohistochemistry; Inflammation - drug therapy; Inflammation - pathology; Lipopolysaccharides - toxicity; Male; Membrane lipids; Mice; Mice, Inbred C57BL; Microglia; Mitogens; Nervous system diseases; Neuroinflammation; Neurons; Oxidative stress; Phospholipids; Plasmalogens - therapeutic use; Proteins; Risk factors; Rodents; Studies
• ISSN: 1742-2094; 1742-2094
• DOI: 10.1186/1742-2094-9-197

Neuroinflammation involves the activation of glial cells in neurodegenerative diseases such as Alzheimer's disease (AD). Plasmalogens (Pls) are glycerophospholipids constituting cellular membranes and play significant roles in membrane fluidity and cellular processes such as vesicular fusion and signal transduction. In this study the preventive effects of Pls on systemic lipopolysaccharide (LPS)-induced neuroinflammation were investigated using immunohistochemistry, real-time PCR methods and analysis of brain glycerophospholipid levels in adult mice. Intraperitoneal (i.p.) injections of LPS (250 μg/kg) for seven days resulted in increases in the number of Iba-1-positive microglia and glial fibrillary acidic protein (GFAP)-positive astrocytes in the prefrontal cortex (PFC) and hippocampus accompanied by the enhanced expression of IL-1β and TNF-α mRNAs. In addition, β-amyloid (Aβ3-16)-positive neurons appeared in the PFC and hippocampus of LPS-injected animals. The co-administration of Pls (i.p., 20 mg/kg) after daily LPS injections significantly attenuated both the activation of glial cells and the accumulation of Aβ proteins. Finally, the amount of Pls in the PFC and hippocampus decreased following the LPS injections and this reduction was suppressed by co-treatment with Pls. These findings suggest that Pls have anti-neuroinflammatory and anti-amyloidogenic effects, thereby indicating the preventive or therapeutic application of Pls against AD.